Terconazole NDC 45802-717

NDC codes

FDA NDC Directory

Product NDC (as listed)45802-717Labeler and product segments. Claims need a package NDC.

Product NDC at billing width45802-0717Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
45802-717-08	45802071708	3 BLISTER PACK in 1 CARTON (45802-717-08) / 1 SUPPOSITORY in 1 BLISTER PACK (45802-717-00)Marketed from Aug 28, 2006

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Terconazole
Generic name (nonproprietary): terconazole
Active ingredients: Terconazole — 80 mg/1
Dosage form: Suppository
Route: Vaginal
Labeler: Padagis Israel Pharmaceuticals Ltd
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 077149
Marketing start: Aug 28, 2006
Listing expires: Dec 31, 2027
Other FDA classes: Azoles (Chemical structure)
Identifiers: Product ID 45802-717_006c6bda-594f-46ce-ba64-d075022ed4b4SPL ID 006c6bda-594f-46ce-ba64-d075022ed4b4SPL set ID 207e9cf2-e8ec-43d7-9c11-46283c9cdb37RxCUI 198245UNII 0KJ2VE664U
Pharmacologic class: Azole Antifungal

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N445802071708 followed by a unit qualifier and the quantity

Package 45802-0717-08. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 11, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Terconazole Vaginal Suppositories, 80 mg are indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As this product is effective only for vulvovaginitis caused by the genus Candida, the diagnosis should be confirmed by KOH smears and/or cultures.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)